Drug intelligence / Profile preview

ga-68-mtp220

Development stage: Phase 1
Lead developer: Molecular Theranostics
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

[Ga-68]MTP220 is a radiopharmaceutical diagnostic agent developed by Molecular Theranostics. It is in preclinical development and designed for use in positron emission tomography (PET) imaging. The compound consists of gallium-68, a positron-emitting radionuclide, chelated to a synthetic peptide that targets specific tumor markers. Its primary therapeutic area is neoplasms (cancers), where it enables the visualization of tumors expressing the relevant molecular target. As with other Ga-68 labeled agents, it works by binding to its target on tumor cells and allowing PET imaging to localize disease sites.

Other names: [ga68]-mtp220

Targets

ED-B (Fibronectin extra domain B)

Beyond the preview

Go deeper on ga-68-mtp220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ga-68-mtp220.

Explore the full profile